Abstract：
UNASSIGNED: To systematically evaluate the efficacy and safety of renin-angiotensin system inhibitors (RASIs) and angiotensin receptor neprilysin inhibitors in preventing the recurrence of atrial fibrillation after atrial fibrillation ablation, we have written this meta-analysis. We systematically searched randomized controlled trials or cohort studies on RASIs and angiotensin receptor neprilysin inhibitor-sacubitril/valsartan (SV) in preventing the recurrence of atrial fibrillation. Two researchers independently screened the literature, extracted the data, and assessed the risk of bias in the included studies. Afterward, the meta-analysis was performed using RevMan 5.3 software. This meta-analysis results showed that the recurrence rate of atrial fibrillation after ablation in subjects using RASIs was lower than that in subjects not using them [relative risk = 0.85, 95% confidence interval (CI) (0.72-0.99), P = 0.03]; the recurrence rate in subjects using SV was lower than that in subjects using RASIs [RR= 0.50, 95% CI (0.37-0.68), P < 0.00001]. These results show that both the use of RASIs and SV can prevent the recurrence of after atrial fibrillation ablation, among which the use of SV is more effective.
摘要：
系统评价肾素-血管紧张素抑制剂（RASI）和血管紧张素受体脑啡肽抑制剂（ARNI）预防房颤消融术后复发的有效性和安全性。我们已经写了这个荟萃分析。我们系统地检索了肾素-血管紧张素抑制剂和血管紧张素受体脑啡肽抑制剂-沙库必曲/缬沙坦（SV）预防房颤复发的随机对照试验或队列研究。两名研究人员独立筛选了文献，提取数据，并评估纳入研究的偏倚风险。之后,荟萃分析使用RevMan5.3软件进行.这项荟萃分析结果表明，使用肾素-血管紧张素抑制剂（RASI）的受试者消融后房颤的复发率低于未使用它们的受试者[RR=0.85，95CI（0.72，0.99），P=0.03];使用沙库必曲/缬沙坦（SV）的受试者的复发率低于使用肾素-血管紧张素抑制剂（RASI）的受试者[RR=0.50，95CI（0.37，0.68），P<0.00001]。这些结果表明，使用肾素-血管紧张素抑制剂（RASI）和沙库必曲/缬沙坦（SV）可以预防房颤消融术后的复发。其中使用舒必曲/缬沙坦（SV）更有效。
